Can Semaglutide Raise Blood Pressure — or Does It Do the Opposite?

You've been told your blood pressure is borderline — and now someone's mentioned semaglutide

That combination of concerns is one our prescribers hear regularly. It's completely understandable to wonder whether adding a new medicine might push things in the wrong direction when your readings are already being watched. The reassuring starting point is that the STEP 1 trial, a 68-week study of semaglutide 2.4 mg published in the New England Journal of Medicine, found that participants lost an average of around 15% of their body weight. Alongside that loss came measurable reductions in systolic blood pressure, waist circumference and inflammatory markers. The mechanism is straightforward in principle: less body weight means less pressure on arterial walls, less fluid retention and a lighter workload for the heart.

Semaglutide also holds a separate UK licence for reducing the risk of major cardiovascular events in eligible adults with established cardiovascular disease. That is distinct from its weight-management licence, but it signals that the regulatory view of the medicine is not one of cardiovascular concern. For most people asking whether semaglutide or Wegovy raises blood pressure, the honest answer is: it is more likely to lower it than raise it, and the size of that reduction tends to track with how much weight is lost.

Worth noting: this does not mean semaglutide replaces antihypertensive medication. Any change to your prescriptions is a conversation for your GP or prescriber.

When blood pressure might nudge up, and why it usually settles

A handful of people do notice slightly higher readings early in treatment, and there are a few plausible reasons for this. Nausea and vomiting, which are common in the first few weeks after starting or increasing the dose, place short-term physiological stress on the body. That stress response can temporarily narrow blood vessels and lift blood pressure. It is not a pharmacological action of semaglutide on blood pressure receptors; it is the body reacting to feeling unwell.

Dehydration is a related factor. If GI symptoms cause someone to drink and eat less than usual, fluid volume can drop enough to trigger compensatory changes in blood pressure regulation. The NHS patient information for semaglutide lists dehydration as something to watch for if vomiting or diarrhoea is severe, and advises contacting a healthcare professional if these symptoms persist. So if readings rise at the start of treatment, the first question is usually how the GI side effects are being managed rather than whether the medicine is directly driving hypertension.

For the vast majority of people, any early fluctuations settle as the body adjusts to the new dose level, typically within the first two to four weeks. The sustained direction of travel, as weight comes off over months, is towards lower blood pressure rather than higher. Pages covering the broader effect Wegovy has on blood pressure and what changes to look out for across treatment explore this in more detail.

If you already take blood pressure medication, here is why monitoring matters

This is arguably the most practical section for readers who arrived at this page with a specific concern. If you are already prescribed amlodipine, ramipril, bisoprolol or any other antihypertensive, losing a significant amount of weight can shift your blood pressure low enough that your existing dose becomes too strong. That is not a side effect of semaglutide per se; it is weight loss working as intended, reducing the cardiovascular load your medication was calibrated to manage.

The result can be readings that look fine on paper but feel off in person: light-headedness when standing up, tiredness, occasional dizziness. A prescriber who knows you are on Wegovy will watch for exactly this, and may recommend your GP checks your antihypertensive dose every few months as weight changes. If you are considering private treatment and wondering about the cost implications of ongoing clinical oversight, the Wegovy cost page sets out what is included in a single transparent price at nume, which covers clinical review at every repeat. The detail on what happens specifically when blood pressure is a factor in your history is something our prescribers address at the initial consultation.

Low blood pressure as a separate concern, and the signs to watch for, are covered on the semaglutide and low blood pressure page if that is what you are looking for.

What this means practically, and when to ask your prescriber

The evidence is consistent enough that existing hypertension is not a blanket reason to rule out semaglutide. It does mean your prescriber needs to know your cardiovascular history and current medication list before treatment starts. A home blood pressure monitor during the first few months is sensible if your readings were already being tracked. Anything that feels like a significant and sustained increase, rather than a brief early fluctuation, should prompt a conversation with your prescribing team rather than waiting for a scheduled review.

If you take other medicines alongside semaglutide and want to understand how they interact, the page on semaglutide and common medicines addresses some of those questions. For a broader look at how Wegovy works as a treatment and what the clinical pathway looks like from the start, the Wegovy treatment page is the right starting point. The question of whether semaglutide actively helps blood pressure rather than simply not harming it is addressed there too. For a broader view of weight-loss treatment options, the weight-loss treatments overview sets out what is available and how the medicines compare at a high level.

If you would like a prescriber to review your specific history, including any blood pressure concerns, you can speak to our prescribers through a free consultation. There is no obligation, and the clinical review covers your cardiovascular history as part of the standard assessment.